Healthcare Jun 23, 2022 10:06 AM (GMT+8) · EqualOcean
Recently, the biological manufacturing enterprise Mojia bio completed a round B financing of more than US $80million. This round of financing was led by Temasek, followed by Sento investment, lyzz capital and other investors. The existing shareholders green capital and food core capital continued to increase their holdings. This round of financing will be used for the industrialization and commercialization of Mojia bio's core bio based products, as well as the R & D of new product pipelines and team expansion. Mojia bio is committed to developing green and environmentally friendly biological manufacturing methods to replace the traditional chemical production technology with high pollution and high energy consumption. Based on its innovative enzyme engineering transformation and biological metabolic pathway transformation platform, as well as its interdisciplinary advantages, Mojia biology has completed the process development of several bulk products and entered the industrialization stage. The company's viridimin ® Series vitamin B5 products will be mass produced in June, 2022.

This text is a result of machine translation.